nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—Bosutinib—EPHA3—cleft lip	0.0176	1	CrCbGaD
Vandetanib—LTK—tongue—cleft lip	0.0167	0.0791	CbGeAlD
Vandetanib—SRC—periosteum—cleft lip	0.0161	0.0765	CbGeAlD
Vandetanib—LTK—mouth—cleft lip	0.0112	0.0532	CbGeAlD
Vandetanib—ERBB3—mouth—cleft lip	0.00612	0.029	CbGeAlD
Vandetanib—TYRO3—telencephalon—cleft lip	0.00482	0.0229	CbGeAlD
Vandetanib—EPHA5—telencephalon—cleft lip	0.00482	0.0229	CbGeAlD
Vandetanib—FLT4—embryo—cleft lip	0.00458	0.0217	CbGeAlD
Vandetanib—ERBB3—embryo—cleft lip	0.00436	0.0207	CbGeAlD
Vandetanib—LTK—head—cleft lip	0.00405	0.0192	CbGeAlD
Vandetanib—FGR—embryo—cleft lip	0.00404	0.0192	CbGeAlD
Vandetanib—RET—embryo—cleft lip	0.00404	0.0192	CbGeAlD
Vandetanib—EPHA8—head—cleft lip	0.00388	0.0184	CbGeAlD
Vandetanib—EGFR—telencephalon—cleft lip	0.00382	0.0181	CbGeAlD
Vandetanib—FYN—embryo—cleft lip	0.00377	0.0179	CbGeAlD
Vandetanib—VEGFA—telencephalon—cleft lip	0.0037	0.0175	CbGeAlD
Vandetanib—TEK—embryo—cleft lip	0.00368	0.0175	CbGeAlD
Vandetanib—ERBB3—telencephalon—cleft lip	0.00355	0.0168	CbGeAlD
Vandetanib—MKNK1—telencephalon—cleft lip	0.00333	0.0158	CbGeAlD
Vandetanib—AXL—telencephalon—cleft lip	0.00328	0.0155	CbGeAlD
Vandetanib—SRC—embryo—cleft lip	0.00327	0.0155	CbGeAlD
Vandetanib—EPHA6—head—cleft lip	0.00324	0.0153	CbGeAlD
Vandetanib—SLK—telencephalon—cleft lip	0.00315	0.0149	CbGeAlD
Vandetanib—FYN—telencephalon—cleft lip	0.00307	0.0145	CbGeAlD
Vandetanib—KDR—embryo—cleft lip	0.00301	0.0143	CbGeAlD
Vandetanib—TYRO3—head—cleft lip	0.003	0.0142	CbGeAlD
Vandetanib—EPHA5—head—cleft lip	0.003	0.0142	CbGeAlD
Vandetanib—TEK—telencephalon—cleft lip	0.003	0.0142	CbGeAlD
Vandetanib—MAP4K5—telencephalon—cleft lip	0.003	0.0142	CbGeAlD
Vandetanib—LYN—head—cleft lip	0.00299	0.0142	CbGeAlD
Vandetanib—BMPR1B—head—cleft lip	0.00294	0.014	CbGeAlD
Vandetanib—MAP3K19—head—cleft lip	0.00294	0.014	CbGeAlD
Vandetanib—EPHB6—telencephalon—cleft lip	0.00286	0.0136	CbGeAlD
Vandetanib—YES1—telencephalon—cleft lip	0.00277	0.0131	CbGeAlD
Vandetanib—SRC—telencephalon—cleft lip	0.00266	0.0126	CbGeAlD
Vandetanib—PDGFRB—embryo—cleft lip	0.00261	0.0124	CbGeAlD
Vandetanib—STK35—head—cleft lip	0.0025	0.0119	CbGeAlD
Vandetanib—MAP2K5—telencephalon—cleft lip	0.00245	0.0116	CbGeAlD
Vandetanib—ABL1—embryo—cleft lip	0.00232	0.011	CbGeAlD
Vandetanib—FLT4—head—cleft lip	0.00232	0.011	CbGeAlD
Vandetanib—RIPK2—head—cleft lip	0.00231	0.0109	CbGeAlD
Vandetanib—FMO1—head—cleft lip	0.00229	0.0108	CbGeAlD
Vandetanib—IRAK4—head—cleft lip	0.00225	0.0107	CbGeAlD
Vandetanib—ERBB3—head—cleft lip	0.00221	0.0105	CbGeAlD
Vandetanib—PDGFRB—telencephalon—cleft lip	0.00212	0.01	CbGeAlD
Vandetanib—MKNK1—head—cleft lip	0.00207	0.00983	CbGeAlD
Vandetanib—RET—head—cleft lip	0.00205	0.00971	CbGeAlD
Vandetanib—FGR—head—cleft lip	0.00205	0.00971	CbGeAlD
Vandetanib—AXL—head—cleft lip	0.00204	0.00967	CbGeAlD
Vandetanib—FMO3—head—cleft lip	0.00198	0.00938	CbGeAlD
Vandetanib—FYN—head—cleft lip	0.00191	0.00905	CbGeAlD
Vandetanib—ABL1—telencephalon—cleft lip	0.00189	0.00895	CbGeAlD
Vandetanib—MAP4K5—head—cleft lip	0.00187	0.00884	CbGeAlD
Vandetanib—TEK—head—cleft lip	0.00187	0.00884	CbGeAlD
Vandetanib—EPHB6—head—cleft lip	0.00178	0.00845	CbGeAlD
Vandetanib—YES1—head—cleft lip	0.00172	0.00817	CbGeAlD
Vandetanib—STK10—head—cleft lip	0.00171	0.00809	CbGeAlD
Vandetanib—SRC—head—cleft lip	0.00166	0.00786	CbGeAlD
Vandetanib—MAP2K5—head—cleft lip	0.00152	0.00723	CbGeAlD
Vandetanib—KDR—head—cleft lip	0.00152	0.00723	CbGeAlD
Vandetanib—ABCC1—telencephalon—cleft lip	0.00144	0.00682	CbGeAlD
Vandetanib—PDGFRB—head—cleft lip	0.00132	0.00626	CbGeAlD
Vandetanib—ABCG2—telencephalon—cleft lip	0.00119	0.00565	CbGeAlD
Vandetanib—ABL1—head—cleft lip	0.00118	0.00558	CbGeAlD
Vandetanib—FYN—Signaling Pathways—FGF8—cleft lip	3.66e-05	4.75e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—FGFR3—cleft lip	3.65e-05	4.73e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—FGF2—cleft lip	3.65e-05	4.73e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—FGF10—cleft lip	3.63e-05	4.71e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—FGF2—cleft lip	3.61e-05	4.68e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—FGF2—cleft lip	3.6e-05	4.66e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—FGFR1—cleft lip	3.59e-05	4.65e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—FGF9—cleft lip	3.59e-05	4.65e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—FGF2—cleft lip	3.56e-05	4.61e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—FGF3—cleft lip	3.54e-05	4.59e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—FGF2—cleft lip	3.54e-05	4.59e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—FGF2—cleft lip	3.51e-05	4.55e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—FGF2—cleft lip	3.51e-05	4.55e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—FGF10—cleft lip	3.5e-05	4.54e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—FGF2—cleft lip	3.5e-05	4.53e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—FGF2—cleft lip	3.48e-05	4.51e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—FGF2—cleft lip	3.47e-05	4.5e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—FGFR2—cleft lip	3.46e-05	4.49e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—NOS3—cleft lip	3.46e-05	4.48e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—FGF10—cleft lip	3.46e-05	4.48e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—FGF9—cleft lip	3.46e-05	4.48e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—FGFR1—cleft lip	3.45e-05	4.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SPRY2—cleft lip	3.43e-05	4.44e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGF7—cleft lip	3.43e-05	4.44e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—FGF2—cleft lip	3.42e-05	4.43e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—MTR—cleft lip	3.41e-05	4.42e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PTCH1—cleft lip	3.41e-05	4.42e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—FGF3—cleft lip	3.4e-05	4.41e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—FGFR3—cleft lip	3.39e-05	4.4e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTCH1—cleft lip	3.34e-05	4.33e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—FGF10—cleft lip	3.34e-05	4.33e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—FGF9—cleft lip	3.31e-05	4.3e-05	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—MYC—cleft lip	3.31e-05	4.29e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SPRY2—cleft lip	3.3e-05	4.28e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGF7—cleft lip	3.3e-05	4.28e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTCH1—cleft lip	3.29e-05	4.26e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—FGF10—cleft lip	3.28e-05	4.25e-05	CbGpPWpGaD
Vandetanib—MKNK1—Disease—MYC—cleft lip	3.27e-05	4.24e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—FGFR3—cleft lip	3.26e-05	4.22e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—NOS3—cleft lip	3.24e-05	4.21e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—FGFR1—cleft lip	3.23e-05	4.18e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—FGF2—cleft lip	3.21e-05	4.17e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—FGF10—cleft lip	3.21e-05	4.16e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—FGFR2—cleft lip	3.17e-05	4.11e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGF8—cleft lip	3.16e-05	4.1e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—FGF10—cleft lip	3.16e-05	4.09e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—FGFR2—cleft lip	3.16e-05	4.09e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—FGF3—cleft lip	3.14e-05	4.07e-05	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—NOS3—cleft lip	3.12e-05	4.04e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FGF3—cleft lip	3.09e-05	4.01e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—FGFR2—cleft lip	3.09e-05	4.01e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—FGFR2—cleft lip	3.09e-05	4e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—FGFR2—cleft lip	3.08e-05	3.99e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—FGF2—cleft lip	3.07e-05	3.98e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—FGF9—cleft lip	3.06e-05	3.97e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—FGFR2—cleft lip	3.05e-05	3.96e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—FGFR3—cleft lip	3.05e-05	3.95e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGF8—cleft lip	3.05e-05	3.95e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—FGFR2—cleft lip	3.04e-05	3.94e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—TCN2—cleft lip	3.04e-05	3.94e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FGF3—cleft lip	3.03e-05	3.93e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—MYC—cleft lip	3.03e-05	3.92e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—FGF10—cleft lip	3.02e-05	3.92e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FGF9—cleft lip	3.02e-05	3.91e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FGF3—cleft lip	2.98e-05	3.86e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—FGF2—cleft lip	2.97e-05	3.85e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—FGF2—cleft lip	2.97e-05	3.85e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—FGF2—cleft lip	2.96e-05	3.84e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FGF9—cleft lip	2.95e-05	3.83e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—FGFR1—cleft lip	2.95e-05	3.83e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—FGF2—cleft lip	2.95e-05	3.82e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—FGFR1—cleft lip	2.94e-05	3.81e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—NOS3—cleft lip	2.93e-05	3.79e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SPRY2—cleft lip	2.92e-05	3.79e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGF7—cleft lip	2.92e-05	3.79e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—FGF10—cleft lip	2.91e-05	3.78e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—FGFR2—cleft lip	2.91e-05	3.78e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FGF9—cleft lip	2.91e-05	3.77e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—FGFR1—cleft lip	2.88e-05	3.73e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—FGFR1—cleft lip	2.88e-05	3.73e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—NOS3—cleft lip	2.87e-05	3.72e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—FGFR1—cleft lip	2.87e-05	3.72e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—FGFR1—cleft lip	2.85e-05	3.69e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—FGF2—cleft lip	2.84e-05	3.69e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTCH1—cleft lip	2.84e-05	3.68e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—FGFR1—cleft lip	2.84e-05	3.68e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—FGF2—cleft lip	2.82e-05	3.66e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—FGFR2—cleft lip	2.81e-05	3.64e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MTHFR—cleft lip	2.81e-05	3.64e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—FGF10—cleft lip	2.79e-05	3.62e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—FGFR3—cleft lip	2.79e-05	3.62e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—FGFR3—cleft lip	2.78e-05	3.61e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—FGFR2—cleft lip	2.77e-05	3.6e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—MYC—cleft lip	2.77e-05	3.59e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTCH1—cleft lip	2.74e-05	3.55e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—FGFR3—cleft lip	2.72e-05	3.53e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—FGFR3—cleft lip	2.72e-05	3.52e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—FGFR1—cleft lip	2.72e-05	3.52e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—FGFR3—cleft lip	2.71e-05	3.51e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MTHFR—cleft lip	2.7e-05	3.51e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGF8—cleft lip	2.7e-05	3.5e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—FGFR3—cleft lip	2.69e-05	3.49e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—FGFR3—cleft lip	2.68e-05	3.47e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—FGFR2—cleft lip	2.68e-05	3.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—FGFR2—cleft lip	2.63e-05	3.41e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—FGF2—cleft lip	2.62e-05	3.4e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—FGFR1—cleft lip	2.62e-05	3.39e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—FGFR1—cleft lip	2.59e-05	3.35e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—FGF10—cleft lip	2.58e-05	3.35e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGF3—cleft lip	2.58e-05	3.34e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—FGFR2—cleft lip	2.58e-05	3.34e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—FGFR3—cleft lip	2.57e-05	3.33e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FGF10—cleft lip	2.54e-05	3.3e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—FGFR2—cleft lip	2.53e-05	3.28e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—FGF2—cleft lip	2.52e-05	3.26e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGF9—cleft lip	2.51e-05	3.26e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—FGFR1—cleft lip	2.5e-05	3.24e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FGF10—cleft lip	2.49e-05	3.23e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGF3—cleft lip	2.48e-05	3.22e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MTHFR—cleft lip	2.48e-05	3.21e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—FGFR3—cleft lip	2.48e-05	3.21e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FGF10—cleft lip	2.45e-05	3.18e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—FGFR1—cleft lip	2.45e-05	3.18e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—FGFR3—cleft lip	2.44e-05	3.17e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—FGFR2—cleft lip	2.43e-05	3.15e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTCH1—cleft lip	2.42e-05	3.14e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGF9—cleft lip	2.42e-05	3.14e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—FGFR1—cleft lip	2.4e-05	3.11e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—TYMS—cleft lip	2.38e-05	3.08e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—FGFR1—cleft lip	2.36e-05	3.06e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—FGFR3—cleft lip	2.36e-05	3.06e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—FGF2—cleft lip	2.36e-05	3.06e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—FGFR2—cleft lip	2.34e-05	3.03e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MTHFR—cleft lip	2.34e-05	3.03e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—NOS3—cleft lip	2.33e-05	3.01e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—FGFR3—cleft lip	2.32e-05	3e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—MYC—cleft lip	2.29e-05	2.97e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—FGFR3—cleft lip	2.27e-05	2.94e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—FGFR1—cleft lip	2.26e-05	2.93e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MTHFR—cleft lip	2.25e-05	2.92e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—FGFR2—cleft lip	2.24e-05	2.91e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—FGFR3—cleft lip	2.23e-05	2.89e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGF3—cleft lip	2.2e-05	2.85e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—FGFR1—cleft lip	2.18e-05	2.83e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—FGF2—cleft lip	2.16e-05	2.8e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—FGF2—cleft lip	2.15e-05	2.79e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGF9—cleft lip	2.14e-05	2.78e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—FGFR3—cleft lip	2.14e-05	2.77e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—NOS3—cleft lip	2.13e-05	2.76e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGF10—cleft lip	2.12e-05	2.75e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MTR—cleft lip	2.11e-05	2.73e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—FGF2—cleft lip	2.1e-05	2.73e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—FGF2—cleft lip	2.1e-05	2.72e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—FGF2—cleft lip	2.09e-05	2.71e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—TYMS—cleft lip	2.09e-05	2.71e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—FGFR1—cleft lip	2.09e-05	2.71e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—FGF2—cleft lip	2.08e-05	2.69e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—MTHFR—cleft lip	2.08e-05	2.69e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—NOS3—cleft lip	2.07e-05	2.69e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—FGF2—cleft lip	2.07e-05	2.69e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—FGFR2—cleft lip	2.07e-05	2.68e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—FGFR3—cleft lip	2.06e-05	2.67e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—NOS3—cleft lip	2.05e-05	2.66e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FGFR2—cleft lip	2.04e-05	2.65e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGF10—cleft lip	2.04e-05	2.65e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FGFR2—cleft lip	2e-05	2.59e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MTHFR—cleft lip	1.99e-05	2.58e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—FGF2—cleft lip	1.98e-05	2.57e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC19A1—cleft lip	1.98e-05	2.56e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—FGFR3—cleft lip	1.98e-05	2.56e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FGFR2—cleft lip	1.97e-05	2.55e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—NOS3—cleft lip	1.96e-05	2.54e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—MYC—cleft lip	1.94e-05	2.52e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—NOS3—cleft lip	1.94e-05	2.51e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—FGFR1—cleft lip	1.93e-05	2.5e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—FGF2—cleft lip	1.91e-05	2.48e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FGFR1—cleft lip	1.9e-05	2.47e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—FGF2—cleft lip	1.89e-05	2.45e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—NOS3—cleft lip	1.89e-05	2.45e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—NOS3—cleft lip	1.86e-05	2.41e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FGFR1—cleft lip	1.86e-05	2.41e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FGFR1—cleft lip	1.83e-05	2.38e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—MTHFR—cleft lip	1.83e-05	2.37e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—FGF2—cleft lip	1.82e-05	2.37e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—FGFR3—cleft lip	1.82e-05	2.36e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGF10—cleft lip	1.81e-05	2.34e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—NOS3—cleft lip	1.8e-05	2.33e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FGFR3—cleft lip	1.8e-05	2.33e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—FGF2—cleft lip	1.79e-05	2.32e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FGFR3—cleft lip	1.76e-05	2.28e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—FGF2—cleft lip	1.75e-05	2.27e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FGFR3—cleft lip	1.73e-05	2.25e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—NOS3—cleft lip	1.73e-05	2.24e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—FGF2—cleft lip	1.72e-05	2.24e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGFR2—cleft lip	1.7e-05	2.2e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—FGF2—cleft lip	1.65e-05	2.14e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TCN2—cleft lip	1.64e-05	2.13e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGFR2—cleft lip	1.64e-05	2.12e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NOS3—cleft lip	1.63e-05	2.11e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—FGF2—cleft lip	1.59e-05	2.06e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGFR1—cleft lip	1.58e-05	2.05e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NOS3—cleft lip	1.57e-05	2.04e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MYC—cleft lip	1.54e-05	2e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—FGF2—cleft lip	1.53e-05	1.98e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGFR1—cleft lip	1.53e-05	1.98e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGFR3—cleft lip	1.5e-05	1.94e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGFR2—cleft lip	1.45e-05	1.88e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—NOS3—cleft lip	1.45e-05	1.88e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGFR3—cleft lip	1.44e-05	1.87e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—FGF2—cleft lip	1.41e-05	1.83e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MYC—cleft lip	1.41e-05	1.83e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NOS3—cleft lip	1.39e-05	1.8e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FGF2—cleft lip	1.39e-05	1.8e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MYC—cleft lip	1.37e-05	1.78e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NOS3—cleft lip	1.37e-05	1.78e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FGF2—cleft lip	1.36e-05	1.76e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MYC—cleft lip	1.36e-05	1.76e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGFR1—cleft lip	1.35e-05	1.75e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NOS3—cleft lip	1.34e-05	1.74e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FGF2—cleft lip	1.34e-05	1.74e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NOS3—cleft lip	1.32e-05	1.71e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MYC—cleft lip	1.3e-05	1.68e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—TYMS—cleft lip	1.29e-05	1.67e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGFR3—cleft lip	1.28e-05	1.66e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—NOS3—cleft lip	1.27e-05	1.65e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MYC—cleft lip	1.25e-05	1.62e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MYC—cleft lip	1.23e-05	1.6e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MYC—cleft lip	1.19e-05	1.55e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGF2—cleft lip	1.16e-05	1.5e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MYC—cleft lip	1.15e-05	1.49e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NOS3—cleft lip	1.14e-05	1.48e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTR—cleft lip	1.14e-05	1.47e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MTHFR—cleft lip	1.13e-05	1.46e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGF2—cleft lip	1.12e-05	1.45e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NOS3—cleft lip	1.1e-05	1.43e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—cleft lip	1.08e-05	1.4e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—cleft lip	1.04e-05	1.35e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGF2—cleft lip	9.87e-06	1.28e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOS3—cleft lip	9.74e-06	1.26e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—cleft lip	9.22e-06	1.19e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—cleft lip	9.08e-06	1.18e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—cleft lip	8.89e-06	1.15e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—cleft lip	8.76e-06	1.13e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NOS3—cleft lip	7.86e-06	1.02e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—cleft lip	7.56e-06	9.81e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—cleft lip	7.29e-06	9.45e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TYMS—cleft lip	6.97e-06	9.03e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—cleft lip	6.45e-06	8.37e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—cleft lip	6.09e-06	7.89e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NOS3—cleft lip	4.24e-06	5.5e-06	CbGpPWpGaD
